NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125

NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.

Sponsor

Memorial Sloan Kettering Cancer Center

---

ClinicalTrials.gov Identifier: NCT05431608

Official Title: Phase I Trial of Concurrent Administration of GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 in Patients With Relapsed or Refractory Multiple Myeloma

First Posted : June 24, 2022

Click here for details on ClinicalTrials.gov

---

GPRC5D-Targeted CAR T Cell MCARH109

MCARH109

Autologous Anti-GPRC5D-CAR-4-1BB-expressing T-cells MCARH109 (Code C176222)

Autologous Anti-GPRC5D CAR-T Cells MCARH109

Autologous Anti-GPRC5D-CAR-4-1BB-expressing T-cells MCARH109

Autologous GPRC5D-targeted CAR T Cells MCARH109

MCARH 109

MCARH-109

MCARH109